125 related articles for article (PubMed ID: 32892174)
1. Alternatives to the Kaplan-Meier estimator of progression-free survival.
Zhang JJ; Sun Z; Yuan H; Wang M
Int J Biostat; 2020 Sep; 17(1):99-115. PubMed ID: 32892174
[TBL] [Abstract][Full Text] [Related]
2. Progression-free survival in oncological clinical studies: Assessment time bias and methods for its correction.
Miltenberger R; Götte H; Schüler A; Jahn-Eimermacher A
Pharm Stat; 2021 Jul; 20(4):864-878. PubMed ID: 33783071
[TBL] [Abstract][Full Text] [Related]
3. Semi-supervised calibration of noisy event risk (SCANER) with electronic health records.
Hong C; Liang L; Yuan Q; Cho K; Liao KP; Pencina MJ; Christiani DC; Cai T
J Biomed Inform; 2023 Aug; 144():104425. PubMed ID: 37331495
[TBL] [Abstract][Full Text] [Related]
4. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
5. The role of censoring on progression free survival: oncologist discretion advised.
Prasad V; Bilal U
Eur J Cancer; 2015 Nov; 51(16):2269-71. PubMed ID: 26259493
[TBL] [Abstract][Full Text] [Related]
6. Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules.
Eaton AA; Zabor EC
Stat Med; 2022 Apr; 41(9):1599-1612. PubMed ID: 35043427
[TBL] [Abstract][Full Text] [Related]
7. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
Campigotto F; Weller E
J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
[TBL] [Abstract][Full Text] [Related]
8. Nonparametric survival estimation when death is reported with delay.
Hubbard AE; Van der Laan MJ; Enanoria W; Colford JM
Lifetime Data Anal; 2000 Sep; 6(3):237-50. PubMed ID: 10949861
[TBL] [Abstract][Full Text] [Related]
9. A joint test for progression and survival with interval-censored data from a cancer clinical trial.
Finkelstein DM; Schoenfeld DA
Stat Med; 2014 May; 33(12):1981-9. PubMed ID: 24500790
[TBL] [Abstract][Full Text] [Related]
10. Some insight on censored cost estimators.
Zhao H; Cheng Y; Bang H
Stat Med; 2011 Aug; 30(19):2381-8. PubMed ID: 21748774
[TBL] [Abstract][Full Text] [Related]
11. The Kaplan-Meier Estimator as an Inverse-Probability-of-Censoring Weighted Average.
Satten GA; Datta S
Am Stat; 2001; 55(3):207-210. PubMed ID: 28845048
[TBL] [Abstract][Full Text] [Related]
12. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
Lesan V; Olivier T; Prasad V
Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
[TBL] [Abstract][Full Text] [Related]
13. Nonparametric estimators of survival function under the mixed case interval-censored model with left truncation.
Shen PS
Lifetime Data Anal; 2020 Jul; 26(3):624-637. PubMed ID: 31930441
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer.
Bagust A; Beale SJ
Med Decis Making; 2018 Oct; 38(7):789-796. PubMed ID: 30125510
[TBL] [Abstract][Full Text] [Related]
15. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies.
Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Kearney M; Stevens JW; Benedict A; Bharmal M
Pharmacoeconomics; 2019 Dec; 37(12):1537-1551. PubMed ID: 31555968
[TBL] [Abstract][Full Text] [Related]
16. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
Rosen K; Prasad V; Chen EY
Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
[TBL] [Abstract][Full Text] [Related]
17. Assessing temporal agreement between central and local progression-free survival times.
Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
Stegherr R; Schmoor C; Beyersmann J; Rufibach K; Jehl V; Brückner A; Eisele L; Künzel T; Kupas K; Langer F; Leverkus F; Loos A; Norenberg C; Voss F; Friede T
Trials; 2021 Jun; 22(1):420. PubMed ID: 34187527
[TBL] [Abstract][Full Text] [Related]
19. When you look matters: the effect of assessment schedule on progression-free survival.
Panageas KS; Ben-Porat L; Dickler MN; Chapman PB; Schrag D
J Natl Cancer Inst; 2007 Mar; 99(6):428-32. PubMed ID: 17374832
[TBL] [Abstract][Full Text] [Related]
20. Evaluating and adjusting for premature censoring of progression-free survival.
Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
